This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Armoiry X, Spath HM, Clarke A, Connock M, Sutcliffe P, Dussart C (2019) Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma. J Mark Access Health Policy. https://doi.org/10.1080/20016689.2019.1648971
ASCO (2021) Value in cancer care. https://www.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/value-cancer-care
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26(8):1547–1573
Cherny NI, de Cries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard J-Y, Schnipper LW, Somerfield MR, Bogaerts J, Karli D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL (2019) Comparative assessment of clinical benefit using the ESMO-Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol 37(4):336–349
Del Paggio JC, Sullivan R, Schrag D, Hopman WM, Azariah B, Pramesh CS, Tannock IF, Booth CM (2017) Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 18(7):887–894
ESMO (2021) ESMO-magnitude of clinical benefit scale: evaluation forms version 1.1. https://www.esmo.org/guidelines/esmo-mcbs/scale-evaluation-forms-v1.0-v1.1/scale-evaluation-forms-v1.1
Europäische Kommission (2018) Innovative payment models for high-cost innovative medicines. https://ec.europa.eu/health/sites/default/files/expert_panel/docs/opinion_innovative_medicines_en.pdf
Fricke U, Hein L, Schwabe U (2020) Neue Arzneimittel 2019. In: Schwabe U, Ludwig WD (Hrsg) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg, New York, S 43–150
G-BA (2020) G-BA setzt Bewertung von Zolgensma aus – Hersteller muss nun vollständige Daten vorlegen. https://www.g-ba.de/presse/pressemitteilungen-meldungen/916/
G-BA (2021) Qualitätsgesicherte Anwendung von Arzneimitteln für neuartige Therapien (ATMP). https://www.g-ba.de/themen/arzneimittel/atmp-qs/
Giorgi D (2017) Le Comité économique des produits de santé et la politique économique du médicament. Ann Pharm Fr 75(5):373–384
Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI (2021) Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open 6(3):100117
HAS (2013) Le service médical rendu (SMR) et l’amélioration du service médical rendu (ASMR). https://www.has-sante.fr/jcms/r_1506267/fr/le-service-medical-rendu-smr-et-l-amelioration-du-service-medical-rendu-asmr
HAS (2014) Pricing & reimbursement of drugs and HTA policies in France. https://www.has-sante.fr/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf
Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS (2020) Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 371:m3434
ICER (2021) Fair pricing, fair access, future innovation. https://icer.org/
IQVIA (2021) Global oncology trends 2021. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2021
IQWiG (2021) Arzneimittel-Zulassung und frühe Nutzenbewertung in Deutschland. https://www.iqwig.de/presse/im-fokus/neue-arzneimittel-zulassung-nutzenbewertung-erstattung/1-arzneimittel-zulassung-und-fruehe-nutzenbewertung-in-deutschland/
Kaltenboeck A, Bach PB (2018) Value-based pricing for drugs. Theme and variations. JAMA 319(21):2165–2166
Kiesewetter B, Cherny NI, Biossel N, Cerisoli F, Dafni U, de Vires EGE, Ghia P, Gökbuget N, Gonzalez-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M, Ribera JM, Scarfo L, Wester R, Hygoura P, Sonneveld P (2020) EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open 5(1):e611
Korchagina D, Millier A, Toumi M, Aballea S, Falisard B (2016) What drives ASMR of orphan drugs? Value Health 19:A599
Kumar H, Fojo T, Mailankody S (2016) An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol 2(9):1130–1140
Lauenroth VD, Kesselheim AS, Sarpatwari A, Stern AD (2020) Lessons from the impact of price regulation on the pricing of anticancer drugs in Germany. Health Aff 39(7):1185–1193
Ludwig WD (2019) Zulassungsverfahren für neue Arzneimittel in Europa. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (Hrsg) Arzneiverordnungs-Report. Springer, Berlin, Heidelberg, New York, S 31–60
Ludwig WD (2020) Zehn Jahre AMNOG – Rückblick und Ausblick. In: Schwabe U, Ludwig WD (Hrsg) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg, New York, S 185–200
McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness thereshold: what it is and what that means. PharmacoEconomics 26(9):733–744
Meissner M (2010) Was ist ein Qaly? Dtsch Arztebl 107(12):A-546
Meyers DE, Jenei K, Chisamore TM, Gyawali B (2021) Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada. JAMA Intern Med 181(4):499–508
NICE (2013) Guide to the methods of technology appraisal 2013. https://www.nice.org.uk/process/pmg9/chapter/the-appraisal-of-the-evidence-and-structured-decision-making
NICE (2021) Glossary. https://www.nice.org.uk/glossary?letter=q
OECD (2021) Value in pharmaceutical pricing. https://www.oecd.org/health/pharmaceutical-pricing.htm
Prescrire (2019) Pourquoi Prescrire. https://prescrire.org/Fr/12/32/0/0/About.aspx
Raftery J, Powell J (2013) Health technology assessment in the UK. Lancet 382(9900):1278–1285
Schaefer R, Hernandez D, Schlander M (2020) Health technology assessment (HTA) in England, France and Germany: What do we know about variations in cancer-related HTA outcomes? Ann Oncol 31(4):S1197
Schleiniger R, Blöchliger J (2006) Der Wert des Lebens aus ökonomischer Sicht: Methoden, Empirie, Anwendungen. Winterthurer Institut für Gesundheitsökonomie (WIG). https://digitalcollection.zhaw.ch/bitstream/11475/16911/3/DerWertdesLebens.Bericht_2006_SC3.4.pdf
Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky L (2015) American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33(23):2563–2577
Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman R, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL (2016) Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34(24):2925–2934
Towse A (2009) Should NICE’s threshold range for cost per QALY be raised? BMJ 338:b181
Van Houtven G, Powers J, Jessup A, Yang JC (2006) Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ 15(8):775–795
Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, Kesselheim AS (2020) Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol 21(5):664–670
Vokinger KN, Hwang TJ, Daniore P, Lee CWC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS (2021) Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy Impliations in the US and Europe. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.2026
Widrig D (2015) Health technology assessment. Springer, Berlin, Heidelberg, New York
Zentner A, Busse R (2011) Bewertung von Arzneimitteln – wie gehen andere Länder vor? GGW 11(1):25–34
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Vokinger, K.N. (2021). Kosten-Nutzen-Bewertung von Arzneimitteln. In: Ludwig, WD., Mühlbauer, B., Seifert, R. (eds) Arzneiverordnungs-Report 2021. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63825-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-63825-5_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-63824-8
Online ISBN: 978-3-662-63825-5
eBook Packages: Medicine (German Language)